

### **HEALTHCARE MONTHLY**

JANUARY 2022

Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies



BioTech / Pharma Life Sciences / Diagnostics **Healthcare Services** 

### **HEADLINE TRANSACTIONS**

ACQUISITION SYNOPSIS

cpap.com



- TM Capital served as exclusive financial advisor to CPAP.com in connection with a strategic investment from Cathay Capital
- Headquartered in Houston, TX, CPAP.com offers machines, masks and accessories via its DTC eCommerce website to patients with obstructive sleep apnea
- · Cathay Capital is a global investment firm managing over \$4.2 billion, with offices in North America, Europe and Asia





- · TM Capital served as exclusive financial advisor to Neoteryx, LLC in connection with its sale to Trajan Group Holdings Limited (Australian Stock Exchange: TRJ)
- Neoteryx, based in Southern California, is a global leader in blood microsampling with operations in the U.S. and Europe
- Trajan is a global developer and manufacturer of analytical and life sciences products and devices used in the analysis of biological, food, water and other environmental samples





- Oracle Corporation (NYSE:ORCL) entered into a definitive agreement to acquire Cerner Corporation (NasdaqGS:CERN)
- Oracle is one of the world's leading enterprise information technology companies
- Cerner provides health care information technology solutions and tech-enabled services to support clinical, financial or operational areas of a hospital or health system in the United States and internationally
- Total Consideration: \$28.3 billion in cash
- Implied Enterprise Value: 5.1x LTM Revenue, 20.1x LTM EBITDA (35% premium)

RESONETICS **GTCR** 




- · The Carlyle Group (NasdagGS:CG) made a strategic investment in Resonetics and will join GTCR, a leading private equity firm, as a meaningful shareholder in the company at an enterprise value of \$2.25 billion
- The Carlyle Group is a global investment firm with \$293 billion AUM that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions.
- · Resonetics engages in laser micro manufacturing and providing contract manufacturing services to the life sciences industry




# HEALTHCARE GROWTH & VALUATION TRENDS


#### **Enterprise Value / LTM Revenue**




#### **Enterprise Value / LTM EBITDA**



#### LTM Revenue Growth




#### LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

#### LTM Stock Price Index





## SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Vifor Pharma AG (SWX:VIFN)	CSL Limited (ASX:CSL)	Vifor is a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies Total Consideration: \$11.7 billon in cash (61% premium)
Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA)	Pfizer Inc. (NYSE:PFE)	Arena Pharmaceuticals develops a diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology, and cardiology Total Consideration: \$6.3 billion in cash (100% premium)
Amunix Pharmaceuticals, Inc.	Sanofi (ENXTPA:SAN)	Amunix discovers and develops protein and peptide therapeutics products for cancers Total Consideration: \$1 billion in cash and \$225 million in contingent consideration

Target	Acquiror	Life Sci / Diagnostics Transactions
Ortho Clinical Diagnostics Holdings plc (NasdaqGS:0CDX)	Quidel Corporation (NasdaqGS:QDEL)	Ortho Clinical offers automated instruments, assays, reagents and other consumables that are used to generate in vitro diagnostic test results Total Consideration: \$5.8 billion in cash and stock (25% premium)
Viroclinics Biosciences B.V. (Summit Partners)	Cerba HealthCare S.A.S.	Viroclinics provides diagnostic and preclinical studies that include drug development for the prevention and treatment of virus infections
Quay Pharmaceuticals Ltd	SGS SA (SWX:SGSN)	Quay Pharmaceuticals provides formulation research and development services for the global biopharmaceutical sector

#### Selected TM Capital Healthcare Experience









#### TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



John Dean Principal jdean@tmcapital.com 404.995.6234



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



Steve Hunter
Managing Director, Sponsor Coverage
shunter@tmcapital.com
404.995.6232



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com

